TLDR Dupilumab for eczema may cause hair loss.
Dupilumab, a biologic therapy approved for atopic dermatitis (AD), was generally considered safe based on over 1,000 adult patient exposures, with conjunctivitis being the most notable side effect. However, a case was reported where a patient developed alopecia areata (AA) within 5 weeks of starting dupilumab treatment for AD, highlighting a potential adverse effect not previously emphasized.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
1 citations
,
July 2025 in “Diagnostics” Dupilumab users have a higher risk of developing alopecia areata.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.